|
|
Post by mannmade on Jan 5, 2018 20:36:54 GMT -5
www.yahoo.com/lifestyle/m/c605b730-be38-3ba7-b8f6-5c26c2a1817e/ss_big-strides-made-in-diabetes.htmlBig Strides Made in Diabetes Care Jan. 5, 2018, at 12:00 p.m. Big Strides Made in Diabetes Care By Serena Gordon HealthDay Reporter (HEALTHDAY) FRIDAY, Jan. 5, 2018 (HealthDay News) -- This past year was a busy, productive one for diabetes research and care. "2017 was a year of progress in our understanding of diabetes and its complications, the tools available to help people manage their diabetes, and attention to the economic and accessibility challenges faced by people with diabetes," said Dr. William Cefalu, chief scientific and medical officer for the American Diabetes Association (ADA). Strides were made in: Artificial pancreas technology Probably the biggest and most anticipated news of 2017 was the rollout of the so-called artificial pancreas. Created by Medtronic, the device combines an insulin pump, a continuous glucose monitor and a computer algorithm that measures blood sugar levels and then delivers insulin automatically when those levels rise. Insulin delivery is also temporarily suspended if blood sugar levels drop too low. The device isn't completely automated yet. People with diabetes still need to know how to count the carbohydrates in their food and enter that information into their insulin pump. And the device still requires people with diabetes to check their blood sugar several times a day and enter that information into the machine -- this is known as "calibrating." The hope is that future versions of the device won't require these steps. Aaron Kowalski, chief mission officer for JDRF (formerly the Juvenile Diabetes Research Foundation), said, "We've waited a long time to see these systems come to market, and while it's not yet perfect, it has opened the door, and there's definitely a benefit." He added that a number of other insulin pump manufacturers and independent companies are working on their own artificial pancreas systems. "Competition is really important and helps drive innovation. The next few years will hold promise," Kowalski added. Improving heart health Heart disease is a significant concern for people with diabetes. New research suggested that long-term use of metformin could reduce the risk of heart disease in people with type 1 diabetes. Other medications have been linked to a reduced risk of heart disease in people with type 2 diabetes. These include Jardiance, Invokana and Victoza. "Cardiovascular disease is the most deadly and expensive complication of diabetes, and a number of recent studies have shown that certain medications also have a strong protective effect against cardiovascular disease in people at high risk for it," Cefalu said. Competition in the continuous glucose monitor (CGM) market The artificial pancreas wasn't the only innovation in diabetes technology in 2017. Another continuous glucose monitoring device (CGM) was approved by the U.S. Food and Drug Administration (FDA). Made by Abbott and called the Libre, this device has been in use in Europe for several years. The major difference in the Libre is that you have to request the blood sugar information. Other devices on the market -- from Dexcom and Medtronic -- send blood sugar information collected by a tiny sensor wire inserted under the skin to a receiver every five minutes or so. The Libre also uses a tiny sensor wire inserted under the skin, but the person with diabetes has to request the information be sent to the receiver. In addition, the Libre also doesn't require any fingerstick calibration as other devices on the market do. "Some people find the constant information provided by continuous glucose monitors to be stressful. With the Libre, you ask when you want the information. It's also a little bit flatter than other CGMs, and it comes in at a much lower price point," Kowalski explained. Improving blood sugar levels in pregnant women with type 1 diabetes One of the most promising uses of CGM technology became evident with the publication of the results of an international study of women with type 1 diabetes who wore the devices during pregnancy. Women with type 1 diabetes have to manage their blood sugar levels very tightly during pregnancy, because high blood sugar levels are associated with birth defects and other pregnancy complications. But this also puts them at risk of developing dangerously low blood sugar levels. Women using CGM spent more time in "target" range than women who didn't. That means their blood sugar was neither too high nor too low for longer periods of time. "This study helped show that mothers and babies do better when the mother [with type 1 diabetes] has a CGM," Kowalski said. The study was published in The Lancet. Insulin speed Novo Nordisk received FDA approval for a new insulin called Fiasp. This insulin starts working in about 2.5 minutes. Currently, Novolog, another product from Novo Nordisk, takes approximately five to 10 minutes to start working. That difference may not seem like much, but unless people with diabetes who are dependent on insulin inject at least five to 10 minutes before they eat, their blood sugar levels may spike too high after eating. It's not always possible or even safe to pre-inject insulin. For example, in a restaurant, you have no way of knowing when your food might arrive, and if you pre-inject and your food is late, you can have a dangerously low blood sugar level. The shorter time it takes Fiasp to work could help prevent spikes in blood sugar after eating, which ultimately leads to better diabetes control. Awareness of costs and increased coverage The cost of insulin has come under sharp scrutiny recently because the cost of some insulin has tripled in about a decade. Sen. Bernie Sanders (I-Vt.) first brought the issue up during the 2016 presidential campaign. The ADA started a campaign called "Make Insulin Affordable" and is working with members of Congress to bring more attention to the issue. This was also the first year that people on Medicare with diabetes could get coverage for CGMs. Initially, Medicare only offered coverage for the Dexcom CGM, but on Jan. 4 the agency announced that it would also cover the Libre CGM. More information Learn more about diabetes from the U.S. National Institute of Diabetes and Digestive and Kidney Diseases. Copyright © 2018 HealthDay. All rights reserved.
|
|
|
|
Post by mannmade on Jan 5, 2018 15:00:28 GMT -5
I believe it is that Afrezza begins to peak in 12 to 15 minutes whereas the RAA's do not until 30 to 45 mins that is the big difference.
|
|
|
|
Post by mannmade on Nov 29, 2017 16:07:16 GMT -5
Thank you...  |
|
|
|
Post by mannmade on Nov 29, 2017 14:25:36 GMT -5
Yes indeed CCI, after a bit of a hiatus I am back on a regular basis following the Board and Mannkind. I have been quietly keeping on top of the story through regular contact with Sports and Baba. Have been accumulating on the recent dips, as I feel like many, the worst is over although still a ways to go... Am cautiously optimistic that Mannkind will see progress this coming 2018 sufficient to finally get the recognition it deserves from the medical community. GLTAL's! |
|
|
|
Post by mannmade on Jan 19, 2017 11:50:33 GMT -5
www.newsmax.com/Health/Health-News/diabetes-shaves-reduces-10/2017/01/18/id/769168/Tags: Diabetes | diabetes | shaves | reduces | 10 | years | life Diabetes Shaves Almost 10 Years From Lifespan Image: Diabetes Shaves Almost 10 Years From Lifespan (Copyright DPC) By Sylvia Booth Hubbard | Wednesday, 18 Jan 2017 11:18 AM Type 2 diabetes reduces lifespan by almost a decade, says a new study published in JAMA. The study, which included more than 512,000 Chinese adults, found that those who were diagnosed with the metabolic disease in middle age lost, on average, nine years of life when compared to people who didn't have the disease. Participants were recruited between 2004 and 2008 and were followed until 2014. Of the group, 6 percent had diabetes (4 percent lived in rural areas while 8 percent lived in urban areas). Researchers found that those with diabetes had twice the risk of dying during the follow-up period, and the increase was higher in rural areas than in urban areas. Diabetes was associated with increased mortality from ischemic heart disease, stroke, chronic kidney disease, chronic liver disease, infection, and cancer of the liver, pancreas and breast. The risk of dying from complications of diabetes (diabetic ketoacidosis or coma) was much greater in rural areas than in urban areas, and was much higher than in high-income countries. The University of Oxford researchers estimated that the 25-year probability of death would be 69 percent among those diagnosed with diabetes at age 50 years compared with 38 percent among otherwise similar individuals without diabetes. The loss of life equaled about nine years of life —10 years in rural areas and eight years in urban areas. More than 29 million Americans have diabetes, and it's the seventh leading cause of death, according to the American Diabetes Association. More than a quarter of Americans age 65 and older have diabetes. Numerous studies have shown that losing weight and following a healthy diet will reduce the risk of developing Type 2 diabetes. A March 2016 study from Britain's Newcastle University found that losing 10 percent of body weight slashed the risk of Type 2 diabetes by up to 90 percent. The study, which was published in Diabetes Care, found that undergoing a crash diet (800 calories) for eight weeks stopped diabetes in its tracks. If patients maintained their weight loss, they remained free of the condition. Even patients who had been diagnosed with diabetes for 10 years were able to reverse the disease.
|
|
|
|
Post by mannmade on Jan 19, 2017 0:49:28 GMT -5
www.upi.com/Health_News/2017/01/18/New-insulin-delivery-smart-patch-shows-promise-in-mouse-study/9451484754427/Tiny, painless microneedles on a smart patch can deliver insulin automatically in response to rising glucose levels are being tested on mice. Photo courtesy American Chemical Society Jan. 18 (UPI) -- Researchers from the United States and China have developed a new smart patch that can monitor blood glucose and automatically deliver insulin painlessly to patients with type 1 diabetes. The smart patch has been shown in tests to be successful at lowering blood glucose in mice. The smart skin patch consists of painless microneedles that contain tiny insulin-carrying pouches, which are designed to break apart quickly and automatically release insulin when blood glucose levels get too high. Researchers tested the smart patch on mice with diabetes and found that the mice were able to maintain consistent concentrations of insulin in their blood. When researchers gave the mice a shot of glucose, blood sugar initially spiked but then dropped to normal levels within two hours. The patch could allow people with type 1 diabetes, who do not make any insulin and are dependent on daily insulin injections and blood sugar monitoring, to have a better quality of life. Patients with advanced type 2 diabetes could also benefit from the technology. The study was published in ACS Nano.
|
|
|
|
Post by mannmade on Jan 1, 2017 18:34:40 GMT -5
Try mnkd cares and see if that makes a difference. Or the co pay card for a year.
|
|
|
|
Post by mannmade on Jan 1, 2017 11:50:07 GMT -5
Aged, Happy new year... Sample pack is given at doc's office. First script is for titration pack and yes it is free.
|
|
|
|
Post by mannmade on Dec 31, 2016 13:21:13 GMT -5
Dr. Oz and The Doctors have both been tried as has been The Today Show etc. Shows like OZ require a significant placement fee plus a television ad buy and a digital media ad buy. Also once you pay for the integration it is no longer a qualified news story and is now a form of advertising subject to all the FDA rules and regs. MannKind has explored many options over the years to get the word out while trying to stay focused on the more basic core business and the blocking and tackling required to run it.
As for the Today Show you either pay a fee as in above or you must qualify independently as a story of organic interest to the news division which unfortunately in the eyes of the current segment producers and story producers AFREZZA does not for some reason. Which I personally find strange especially during November.
I think one thing that is greatly overlooked despite lower than favorable script numbers it is a very well run company. Quality control is high, you never hear any negative issues from patients or PWD except perhaps for insurance issues, etc which are out of their control.
|
|
|
|
Post by mannmade on Dec 31, 2016 13:08:11 GMT -5
Exactly as Sports states... They are building a business from the ground up. They are taking the initiative to do something.... They are part of the solution NOT the solution... as many might hope for... AND "hope is not a strategy..."
|
|
|
|
Post by mannmade on Dec 25, 2016 18:43:52 GMT -5
www.usatoday.com/story/news/politics/2016/12/24/soaring-insulin-prices-prompt-insurance-shift/95780148/Soaring insulin prices prompt insurance shift Jayne O'Donnell , USA TODAY 1:42 p.m. EST December 24, 2016 636180872552420086-Mindy-Bartleson-Headshot.jpg (Photo: Family photo) Many parents of diabetic children and adults suffering with type 1 or type 2 diabetes are bracing for changes in insurance coverage of their insulin next year, as prices of the vital medication continue to soar. Higher insurance deductibles and changes in the prescription brands covered by some insurers are raising concerns among some people with diabetes. CVS Caremark, a pharmacy benefit manager (PBM), will no longer cover the insulin brand Lantus in favor of a new biosimilar version, Basaglar. Biosimilars are considered the generic versions of "biologic" drugs that are based on natural sources. The company also announced a program last week to further keep diabetes costs down, following a similar move in August by competitor Express Scripts. Diabetes is an epidemic in the United States, affecting nearly 10% of the population or about 29 million people, according to the Centers for Disease Control and Prevention. Of those, more than 8 million people are undiagnosed. Type 1 diabetes — often still called juvenile diabetes — can occur when people are children or adults. Type 2 diabetes is becoming more common with the increase in obesity and sedentary behavior. ADVERTISING inRead invented by Teads Prices for Humalog and many insulin brands have increased from about $300 to $500 between January 2013 to October 2016, according to drug discount search company GoodRx. Lantus increased about 60% — from $240 to $380 — in the same time period, GoodRx says. Henry Anhalt is a pediatric endocrinologist and chief Henry Anhalt is a pediatric endocrinologist and chief medical officer of the T1D Exchange. (Photo: T1D Exchange) "It’s definitely unfortunate prices are going up so much and impacting the people who need it to stay alive," says Henry Anhalt, an Englewood, N.J., pediatric endocrinologist. "But I think a big part of the problem is how much (insurers) cover and how much they fight you." The amount of insulin a diabetes patient needs every day depends on what they are going to eat, how much they will exercise and their stress level, says Anhalt, chief medical officer of the T1D Exchange, which is researching ways to better manage diabetes and runs an online community for people with type 1 diabetes. Changes in the formularies — the lists of drugs covered by insurers and pharmacy benefit managers (PBMs) — make many patients anxious, says Anhalt, Read more: World Diabetes Day: How one diabetic went from life on a schedule to having more control Feeling Bern'd: Tweets from Sanders' account send Eli Lilly shares tumbling But Troyen Brennan, a physician and chief health officer at CVS Caremark, says he's heard "very little complaint with regard to stress levels." Basaglar has been proven to be "exactly equivalent if not slightly better," he says. Patients who have a bad reaction to a change in insulin can request an exception to the formulary, Brennan adds. Kristina Blake has type 1 diabetes and insurance through the city of San Diego, her previous employer. Her deductible has increased by 400%, so she "will be dealing with the retail prices next year," she says. She is considering switching to Basaglar for her insulin pump. Because she will always need insulin, Blake says, "I accept that I am a "cash cow." Until insurers started fighting back against price increases by raising deductibles and changing formularies, the companies' reactions to price hikes tended to get more attention than the actual prices. That's starting to change. In the past four years, Blake says, her receipts show the price for three vials of Humalog nearly quadrupled, adding that it's not "a new and improved medication." "That's disgusting," she says. Drugmakers say price increases are necessary to fund innovation and note that the portion of the price going to PBMs and wholesalers is confidential. The PBM trade group says the industry has little choice but to fight back. "Employers, unions and government programs that offer these benefits don’t have much choice but to spend their resources on competitively priced (medications) that offer the same or better value," says Mark Merritt, CEO of the trade group Pharmaceutical Care Management Association. Nearly $5,000 is spent on average per diabetes patient every year on medical expenses that could have been avoided if patients had taken their diabetes medications as prescribed, according to Express Scripts. Improperly treated diabetes can lead to loss of limbs, kidney function and vision. Mindy Bartleson, 24, was diagnosed with type 1 diabetes when she was 7 and lost good insurance coverage when her father died of cancer when she was 12. "I remember what it was like to be floating around trying to get on a low-income insurance," says Bartleson, a program assistant with the College Diabetes Network. "After I gradated from college and got to switch to a new insurance company, my stress level went down because I wasn’t in survival mode."
|
|
|
|
Post by mannmade on Dec 21, 2016 11:12:54 GMT -5
He's a scientist and they tend to be low key and cautious. The fact that he did says he found it amazing is big. Remember he is not in the business of promoting drugs and devices. JDRF is looking for a cure and so to him, imho, AFREZZA is just one more tool or arrow in the quiver. He still uses a pump so he has not really taken full advantage of what AFREZZA seems to offer to us non-diabetic investor types. Wonder what basil he uses?
|
|
|
|
Post by mannmade on Dec 20, 2016 13:00:13 GMT -5
medicalxpress.com/news/2016-12-bionic-pancreas-successfully-blood-sugar.htmlHome Diabetes December 20, 2016 Bionic pancreas system successfully controls blood sugar without risk of hypoglycemia December 20, 2016 The bionic pancreas system developed by Boston University (BU) investigators proved better than either conventional or sensor-augmented insulin pump therapy at managing blood sugar levels in patients with type 1 diabetes living at home, with no restrictions, over 11 days. The report of a clinical trial led by a Massachusetts General Hospital (MGH) physician is receiving advance online publication in The Lancet. "For study participants living at home without limitations on their activity and diet, the bionic pancreas successfully reduced average blood glucose, while at the same time decreasing the risk of hypoglycemia," says Steven Russell, MD, PhD, of the MGH Diabetes Unit. "This system requires no information other than the patient's body weight to start, so it will require much less time and effort by health care providers to initiate treatment. And since no carbohydrate counting is required, it significantly reduces the burden on patients associated with diabetes management." Developed by Edward Damiano, PhD, and Firas El-Khatib, PhD, of the BU Department of Biomedical Engineering, the bionic pancreas controls patients' blood sugar with both insulin and glucagon, a hormone that increases glucose levels. After a 2010 clinical trial confirmed that the original version of the device could maintain near-normal blood sugar levels for more than 24 hours in adult patients, two follow-up trials – reported in a 2014 New England Journal of Medicine paper – showed that an updated version of the system successfully controlled blood sugar levels in adults and adolescents for five days. Another follow-up trial published in The Lancet Diabetes and Endocrinology in 2016 showed it could do the same for children as young as 6 years of age. While minimal restrictions were placed on participants in the 2014 trials, participants in both spent nights in controlled settings and were accompanied at all times by either a nurse for the adult trial or remained in a diabetes camp for the adolescent and pre-adolescent trials. Participants in the current trial had no such restrictions placed upon them, as they were able to pursue normal activities at home or at work with no imposed limitations on diet or exercise. Patients needed to live within a 30-minute drive of one of the trial sites – MGH, the University of Massachusetts Medical Center, Stanford University, and the University of North Carolina at Chapel Hill – and needed to designate a contact person who lived with them and could be contacted by study staff, if necessary. The bionic pancreas system – the same as that used in the 2014 studies – consisted of a smartphone (iPhone 4S) that could wirelessly communicate with two pumps delivering either insulin or glucagon. Every five minutes the smartphone received a reading from an attached continuous glucose monitor, which was used to calculate and administer a dose of either insulin or glucagon. The algorighms controlling the system were updated for the current trial to better respond to blood sugar variations. While the device allows participants to enter information about each upcoming meal into a smartphone app, allowing the system to deliver an anticipatory insulin dose, such entries were optional in the current trial. If participants' blood sugar dropped to dangerous levels or if the monitor or one of the pumps was disconnected for more than 15 minutes, the system would alerted study staff, allowing them to check with the participants or their contact persons. Study participants were adults who had been diagnosed with type 1 diabetes for a year or more and had used an insulin pump to manage their care for at least six months. Each of 39 participants that finished the study completed two 11-day study periods, one using the bionic pancreas and one using their usual insulin pump and any continous glucose monitor they had been using. In addition to the automated monitoring of glucose levels and administered doses of insulin or glucagon, participants completed daily surveys regarding any episodes of symptomatic hypoglycemia, carbohydrates consumed to treat those episodes, and any episodes of nausea. On days when participants were on the bionic pancreas, their average blood glucose levels were significantly lower – 141 mg/dl versus 162 mg/dl – than when on their standard treatment. Blood sugar levels were at levels indicating hypoglycemia (less than 60 mg/dl) for 0.6 percent of the time when participants were on the bionic pancreas, versus 1.9 percent of the time on standard treatment. Participants reported fewer episodes of symptomatic hypoglycemia while on the bionic pancreas, and no episodes of severe hypoglycemia were associated with the system. The system performed even better during the overnight period, when the risk of hypoglycemia is particularly concerning. "Patients with type 1 diabetes worry about developing hypoglycemia when they are sleeping and tend to let their blood sugar run high at night to reduce that risk," explains Russell, an assistant professor of Medicine at Harvard Medical School. "Our study showed that the bionic pancreas reduced the risk of overnight hypoglycemia to almost nothing without raising the average glucose level. In fact the improvement in average overnight glucose was greater than the improvement in average glucose over the full 24-hour period." Damiano, whose work on this project is inspired by his own 17-year-old son's type 1 diabetes, adds, "The availability of the bionic pancreas would dramatically change the life of people with diabetes by reducing average glucose levels – thereby reducing the risk of diabetes complications – reducing the risk of hypoglycemia, which is a constant fear of patients and their families, and reducing the emotional burden of managing type 1 diabetes." A co-author of The Lancet report, Damiano is a professor of Biomedical Engineering at Boston University.
|
|
|
|
Post by mannmade on Dec 13, 2016 18:10:57 GMT -5
Tags: Cancer | Diabetes | FDA | diabetes | bladder | cancer Diabetes Drug May Hike Bladder Cancer Risk: FDA Image: Diabetes Drug May Hike Bladder Cancer Risk: FDA (Copyright Fotolia) Tuesday, 13 Dec 2016 01:55 PM www.newsmax.com/Health/Health-News/FDA-diabetes-bladder-cancer/2016/12/13/id/763719/?hl=1&noRedirect=1 A diabetes drug taken by patients to control blood sugar levels may increase the risk of bladder cancer, federal regulators warn. The U.S. Food and Drug Administration has announced it is updating the drug's labeling to reflect this concern. The drug, which is made by Takeda Pharmaceuticals, is marketed under a number of brand names, including Actos, Actoplus Met, Actoplus Met XR, Duetact, and Oseni. Pioglitazone is approved to improve blood sugar control, along with diet and exercise, in adults with type 2 diabetes. Pioglitazone works by increasing the body’s sensitivity to insulin, a natural hormone that helps control blood sugar levels. Untreated, type 2 diabetes can lead to serious problems, including blindness, nerve and kidney damage, and heart disease. The agency added a warning about the increased risk for bladder cancer to the drug's label in 2011 based on interim results of a 10-year epidemiological study of patients with diabetes. The data suggested that this cancer risk rose as the dose and treatment duration increased, the agency says. According to the FDA, the research on the drug is complicated and had yielded conflicting results. SPECIAL: Gingrich and Reagan Video Goes Viral. See it Now. Learn More But, after a review, the agency said in a news release that it has concluded – again –that pioglitazone may be linked to an increased risk for bladder cancer, and it is updating the medication’s label to describe the additional studies it reviewed. The revised labeling advises clinicians not to prescribe pioglitazone for patients with active bladder cancer and to exercise caution when using it in patients with a history of the cancer. |
|
|
|
Post by mannmade on Dec 12, 2016 16:34:25 GMT -5
Is that normal for local news to get broadcast in different states? ABC is obviously a national channel, but how does the local team broadcast it? Did they just use the patient/doctor video and add their own commentary on it? Or did they just use another channel's news team also? Listened to the video with headphones on and heard something pretty cool that I missed the first time on my speakers. Listen at the following intervals 1:05- hmmm 1:13- can children use that 1:31- wow Sounds like whoever's voice was responsible was pretty impressed with the video. I'll bet they tell their friends and family members about it if they know someone who's diabetic. Hopefully all this momentum turns into results! Having worked in local television for 25 years I can tell you it depends on the circumstances. However, if it is an unpaid story picked up by one of the local owned stations then it could be a shared story as they often pool resources like medical reporter/reporting with the group since most of those stories are never really local in orgin. This can also be shared in the same manner with the affiliated stations. If it is a paid for content segment, which it does not appear to be, otherwise it would have to be fully disclosed then they would have a media strategy against what markets pursuant to the sponsor's media plan/strategy. |
|
